Designed to change the existing standard of care, the Sensible Platform has a 10-minute time-to-result, comparative test pricing, and can deliver lab-quality PCR results
The Sensible PCR Platform was originally designed to support Curative’s next generation of testing operations. (Credit: National Cancer Institute on Unsplash)
US-based health services company Curative has announced the spin-off of Sensible Diagnostics to commercialise the point-of-care polymerase chain reaction (PCR) testing platform, dubbed, the Sensible PCR Platform.
The new Sensible PCR Platform was originally designed to support the next-generation testing operations of Curative.
According to the company, the platform combines speed, affordability, and accuracy for an easy drop-in upgrade for current point-of-care testing workflows.
Designed to change the existing standard of care, the Sensible Platform has a 10-minute time-to-result, comparative test pricing and can deliver lab-quality PCR results.
Curative CEO and co-founder Fred Turner said: “We are excited to be rolling out Sensible Diagnostics to bring a revolutionary, efficient PCR 10-minute desktop testing platform to the masses.
“This device is truly a game changer for diagnostics testing in retail clinics, urgent care, and beyond, and will provide fast, accurate, and affordable results.”
The PCR testing platform was developed using more than two years of experience performing over two million molecular point-of-care tests in the field when Curative was initially focusing on diagnostics.
The platform’s design is simple and has fewer parts and process steps. This minimises the common mistakes and makes the test safer which can offer affordable results, the health services company said.
Curative said that the test prices are comparable with lateral flow antigen testing. The company believes that the Sensible Diagnostics’ platform will soon replace the lateral flow immunoassay testing.
Sensible Diagnostics CEO and co-founder Ernest Templin said: “We learned a lot about diagnostics testing from the pandemic, and in conjunction with our extensive knowledge in the field, we wanted to build a PCR testing platform that would deliver on speed and accuracy while keeping costs low.
“This platform has a pricing structure that is competitive with lateral flow testing and delivers a PCR test result that is exactly the same as one you would get from a lab.”
The Covid-19 testing business of Curative gave rise to Sensible Diagnostics and its point-of-care testing platform.
Curative is no longer in the diagnostic testing business. The company is now providing firms in Texas with a health insurance plan that has zero out-of-pocket cost for members.